David Frey is a Principal in KPMG’s Advisory practice. Based in Boston, David is the leader for KPMG’s life sciences industry concentration in the New England & Upstate New York region. He applies more than 25 years of experience in strategic planning and transformation advisory to assist life sciences clients in achieving their growth, profit and protection objectives. Prior to relocating to Boston in late-2019, he spent most of the last two decades working in China and across Asia Pacific. Under David’s leadership, KPMG's life sciences team in Asia supported an industry leading client in a number of important areas including optimizing cost-to-serve through a redesign of the distribution network (medical device division), CAR-T market opportunity assessment and risk profiling for China (pharmaceutical division), enhancing patient experience through innovative digital platforms (pharmaceutical division), and optimizing product profitability by developing sophisticated data & analytics capabilities (consumer division). For more than two decades, David has advised multinational corporations on their most critical growth and transformation objectives in the USA and Asia. While in Asia, David’s views were called upon regularly by both western governments and the China government, having served as an expert witness at a US Congressional Commission on China’s Five Year Plans, chairing roundtable sessions at China’s prestigious Party School, and hosting a series of multi-lateral sessions in the USA, Europe, China and Japan with the Development Research Center (DRC) of the China State Council regarding the country's urbanization path. He is regularly invited to participate in closed-door discussions with Ambassadors, government ministers, and company boards on the opportunities and challenges of operating efficiently and profitably in China.